About CUE-101 and the Phase 1 Trial CUE-101 is Cue Biopharma’s most advanced clinical stage drug candidate from the CUE-100 series of interleukin 2 (IL-2)-based biologics.

Three-phase voltage source converter (VSC) systems are widely used in the industry. The open-switch faults of VSC systems are not noticeable, but they can result in a major disaster. Aimed at this ...

SERENA-6 is the first global, double-blind, registrational Phase III trial to use a ctDNA-guided approach to detect the emergence of endocrine resistance and inform a switch in therapy before ...

Heliospace Heliospace NASA SBIR Phase II awards support in-depth development of R&D ideas whose feasibility has been established in Phase I and that are likely to result in a commercial product.

Topline results from the Phase 2 trial show improved survival in untreated mPDAC patients using elraglusib with chemotherapy. Quiver AI Summary Actuate Therapeutics, Inc. announced that the ...

A phase converter provides three-phase power from a single-phase source. Old-style mechanical converters use a hybrid motor/generator, while electronic converters use capacitors and other devices to ...

EP: 3. Phase 3 HIV Treatment Switch Studies: Key Findings From Recent Clinical Trials EP: 4. HIV Therapy Without Integrase Inhibitor: Practical Advantages and Targeted Patient Populations EP: 5.

AstraZeneca has made the decision to end the CAPItello-280 trial evaluating capivasertib in patients with metastatic castration-resistant prostate cancer.

Phase 3 OMAHA-004 study of CYP11A1 inhibitor opevesostat versus next-generation hormonal agent (NHA) switch in patients with metastatic castration-resistant prostate cancer (mCRPC) after 1 prior NHA.

OMAHA-003: A phase 3 study of CYP11A1 inhibitor opevesostat versus next-generation hormonal agent (NHA) switch in metastatic castration-resistant prostate cancer (mCRPC) after NHA and taxane-based ...

Merus N.V. has announced the dosing of the first patient in a phase 2 trial assessing petosemtamab, a new monotherapy for heavily pretreated metastatic colorectal cancer (mCRC).